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Abstract
Background: High mammographic density has been correlated with a 4-fold to 6-fold increased risk of developing
breast cancer, and is associated with increased stromal deposition of extracellular matrix proteins, including
collagen I. The molecular and cellular mechanisms responsible for high breast tissue density are not completely
understood.
Methods: We previously described accelerated tumor formation and metastases in a transgenic mouse model of
collagen-dense mammary tumors (type I collagen-α1 (Col1α1)tm1Jae and mouse mammary tumor virus - polyoma
virus middle T antigen (MMTV-PyVT)) compared to wild-type mice. Using ELISA cytokine arrays and multi-color flow
cytometry analysis, we studied cytokine signals and the non-malignant, immune cells in the collagen-dense tumor
microenvironment that may promote accelerated tumor progression and metastasis.
Results: Collagen-dense tumors did not show any alteration in immune cell populations at late stages. The
cytokine signals in the mammary tumor microenvironment were clearly different between wild-type and collagen-
dense tumors. Cytokines associated with neutrophil signaling, such as granulocyte monocyte-colony stimulated
factor (GM-CSF), were increased in collagen-dense tumors. Depleting neutrophils with anti-Ly6G (1A8) significantly
reduced the number of tumors, and blocked metastasis in over 80 % of mice with collagen-dense tumors, but did
not impact tumor growth or metastasis in wild-type mice.
Conclusion: Our study suggests that tumor progression in a collagen-dense microenvironment is mechanistically
different, with pro-tumor neutrophils, compared to a non-dense microenvironment.
Keywords: Extracellular matrix, Tumor microenvironment, Collagen, Tumor associated neutrophils, Breast cancer,
MMTV-PyVT, Stroma, Cytokines
Background
Although much breast cancer research focuses on the
genetic abnormalities seen in cancer cells compared to
normal breast epithelial cells, emerging data reveal that
components of the extracellular matrix (ECM) and cells
in the microenvironment are key regulators of tumor
progression and metastasis. Women with 75 % or
greater mammographically dense breast tissue are four
to six times more likely to develop breast carcinoma
than women with less than 10 % mammographically
dense tissue [1, 2]. As the molecular and cellular mecha-
nisms responsible for high breast tissue density are not
completely understood, many studies rely on in vivo and
in vitro models of density to discover new preventative,
prognostic, and therapeutic targets that will reduce
breast cancer risk in patients with high breast tissue
density. Much of the in vitro work has focused on the
response of mammary epithelial cells to collagen-dense
matrices in the regulation of proliferation and invasive-
ness [3, 4].
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It has been shown that mammographic tissue density
corresponds to alterations in stromal composition [5–7].
High mammographic tissue density is largely attributed
to increased levels of the ECM protein, collagen [8–11].
To better understand the role of increased collagen
density, we utilize a mouse model in which the Collagen
1α1 gene is mutated to make the molecule resistant to
collagenase, resulting in decreased collagen turnover and
a net increase in stromal collagen (Col1α1tm1Jae) [12].
These animals are crossed to the mouse mammary
tumor virus-polyoma middle T antigen (MMTV-
PyVT) model, which is commonly used because it is
comparable with human breast disease, it progresses
from premalignant to malignant tumor and to lung me-
tastasis. Not only is the morphology similar to that in
human disease, but also the biomarkers expressed in
PyVT tumors are consistent with those associated with
poor outcome in humans [13, 14]. PyVT tumors arising
in the collagen-dense (COL) Col1α1 background have a
three-fold increase in tumor formation and lung metasta-
sis compared to tumors arising in wild-type (WT) mice.
The exact mechanism by which increased collagen de-
position leads to increased metastasis is not entirely
clear. However, we previously noted an increase in the
stromal cell populations surrounding tumors within
collagen-dense environments, suggesting activation of the
stromal compartment [12].
The breast tumor microenvironment is composed of
ECM proteins and both malignant and non-malignant
cells. Of the non-malignant, CD45+ immune cells, both
innate and adaptive cells are present in the tumor
microenvironment. T cells (CD8+ cytotoxic cells, CD4+
helper T cells, γδ T cells) and natural killer (NK) cells
play vital anti-tumor roles before tumor cells are able to
evade immune surveillance [15, 16]. Myeloid cells, on
the other hand, have been shown to often have pro-tumor
functions in breast cancer. Tumor cells can educate and
influence macrophages via specific cytokine signaling
crosstalk [17]. Tumor-associated macrophages (TAMs)
can enhance tumor cell migration and invasion, stimulate
angiogenesis, remodel the ECM, and aid breast cancer
metastasis [18–20]. Tissue studies from prophylactic
mastectomies show that highly mammographically dense
tissue is characterized by decreased alternatively activated
(M2) macrophages in the stroma and CD45+ immune
cells in the epithelium [10].
Emerging evidence also suggests neutrophils may be
active players in cancer progression. Similar to macro-
phages, but much less understood in breast cancer,
neutrophils are thought to promote tumor growth by
reducing proinflammatory factors, remodeling the
ECM with proteases that also aid in angiogenesis and
increasing metastasis [21–23]. Tumor-associated neutro-
phils (TANs), in addition to TAMs, can reduce cytotoxic
T cell activity that would kill tumor cells, leading to tumor
growth [24]. TANs contribute to angiogenesis through
matrix metalloproteinase 9 (MMP-9) in human fibrosar-
coma and prostate cancer cells [25]. Neutrophil involve-
ment in metastasis in different breast cancer models has
been uncertain due to conflicting results [26]. In the PyVT
model, depleting neutrophils increases the number of me-
tastases per lung [27]. In contrast, depletion of neutrophils
in the orthotopic 4T1 mouse mammary carcinoma de-
creases the number of lung metastases [28].
Here we investigate the non-malignant, immune cells
present in the collagen-dense tumor microenvironment
that may promote tumor progression and metastasis. In
this study, we report that a pro-tumor immune cell and
cytokine profile characterize the collagen-dense mouse
mammary tumor microenvironment. We find an inher-
ent difference in certain cytokine levels in WT versus
collagen-dense tumors. These signals support the re-
cruitment and activation of neutrophils in the collagen-
dense tumor microenvironment. Our results suggest
that a collagen-dense tumor microenvironment can tip
the balance between a tumor promoting and tumor sup-
pressing phenotype of neutrophils. Depleting neutrophils
significantly slowed the formation of new tumors, and re-
duced tumor burden and lung metastasis only in tumors
arising in the collagen-dense tumor microenvironment,
but not in WT MMTV-PyVT mice. These findings
suggest that tumor progression in a collagen-dense
microenvironment, compared to non-dense microen-
vironments, occurs through a distinct subpopulation
of immune cell effectors.
Methods
Mice
Mice were bred and maintained at the University of
Madison – Wisconsin under the approval of the Uni-
versity of Wisconsin Animal Care and Use Committee
(approved animal protocol number: M01668). Trans-
genic male mice expressing the polyoma virus middle
T antigen under the direction of the mammary mouse
tumor virus promoter (MMTV-PyVT) in the Friend
virus B type (FVB) background (originated from The
Jackson Laboratory, Bar Harbor, ME, USA) were used
as a model of breast cancer that develops spontan-
eous tumors and metastasizes to the lung [14]. These
mice were crossed to female mice heterozygote for
the Col1α1 mutation in the C57BL/6/129 background
(originated from The Jackson Laboratory). The Co1α1
mutation renders the alpha 1 chain of collagen I
uncleavable by collagenase and increases collagen in
the tissue due to decreased remodeling [29]. The result-
ing mice were either positive for the MMTV-PyVT
(tumor mice) or negative (normal mice), and they were
either WT for the Col1α1 mutation (WT) or heterozygote
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(COL). Genotyping by polymerase chain reaction (PCR)
was performed on DNA extracted from tail biopsies.
Tissue collection
Female mice were examined for palpable tumors starting
at 8 weeks. At 15 weeks of age, matched sibling pairs of
WT and COL mice with tumors were anesthetized with 4
% isofluorane. Blood was collected via retro-orbital proced-
ure into an ethylenediaminetetraacetic acid (EDTA) (1.3
mg/ml of blood) collection tube (Sarstedt, Numbrecht,
Germany). Mice were then perfused intracardially with 0.9
% sodium chloride (Abbott Laboratories, Chicago, IL,
USA) supplemented with 1 unit of heparin (Hospira, Lake
Forest, IL, USA). Mammary gland tumors and spleens
were harvested and placed in high glucose DMEM (Gibco,
Grand Island, NY, USA) supplemented with 10 % fetal
bovine serum (FBS, Gemini Bio Products, Baltimore,
MD, USA) and 1× antibiotic antimycotic solution
(Corning, Corning, NY, USA) for ELISA cytokine
array and flow cytometry experiments. Tumors from
the fourth or fifth (right or left) mammary glands and
the lungs were harvested and fixed in 10 % buffered
formalin (Thermo Fisher Scientific, Kalamazoo, MI, USA).
Spleens were weighed and cut in half: one half was placed
in DMEM with 10 % FBS and 1× antibiotic antimycotic
for flow cytometry experiments, and the other half was
fixed in 10 % buffered formalin. Tumors were weighed
and approximately 150 mg of tumor was used per mice
per flow cytometry experiment.
ELISA plate array
To prepare the cell lysate, 100 mg of fresh tumor from
WT and COL tumor mice was placed in 1 ml of cell lysis
buffer (Signosis, Inc., Sunnydale, CA, USA). Tumors were
homogenized on ice in a PowerGen 125 homogenizer
(Fisherbrand, Pittsburgh, PA, USA) for one minute.
Lysates were sonicated at 20 % power for 10 seconds
three times using a Sonic Dismembrator Model 500
(Fisher Scientific) with a Branson tip Model 102 converter.
The samples were centrifuged at 10,000 RPM for 5
minutes. The supernatant was then aliquoted and frozen
at −80 °C until ready to use.
Mouse Cytokine ELISA Plate Array (Chemilumines-
cence) (Signosis, Inc.) is a 96-well plate divided into four
sections; each section has three columns for one sample.
Each section also has 23 specific cytokine capture anti-
bodies coated onto each well and one blank well. Samples
were thawed and diluted to 10 μg per 100 μl per well.
Briefly, each well was incubated with 100 μl of sample for
2 hours, followed by biotin-labeled antibody mixture for 1
hour with gentle shaking, then with strepavidin-HRP
conjugate for 30 minutes with gentle shaking, then
finally with substrate solution for 2 minutes. The plate was
read on a Fluoroskan Ascent™ FL microplate fluorometer
using the Ascent™ Software (Thermo Scientific, Waltham,
MA, USA).
Single cell isolation
Single cells were obtained by cutting tumors and spleens
into small pieces and digesting tumors with 0.028 W/ml
of Liberase TM Research Grade (Roche, Mannheim,
Germany), 20 μg/ml of DNase I, and 1× antibiotic anti-
mycotic in DMEM with 10 % FBS for 1 hour at 37 °C
with 250 RPM agitation. Digestion was facilitated by pip-
etting up and down every 15 minutes. The cell suspen-
sion was filtered through a 70-μm and 40-μm nylon cell
strainer (BD Biosciences, Franklin Lakes, NJ, USA). Red
blood cells were lysed from tumor and spleen single cell
suspensions with lysis buffer (Sigma, St. Louis, MO, USA),
and cells were resuspended in wash buffer (3 % FBS in
PBS, Gibco, Grand Island, NY, USA).
Flow cytometry
Cells were resuspended at 106 cells per 100 μl of wash
buffer and blocked with Fc block (anti CD16/CD32, BD
Biosciences) for 5 minutes at 4 °C. For the myeloid cell
flow panel, 106 cells were incubated with Alexa Fluor®
488-F4/80 (clone BM8, Invitrogen, Carlsbad, CA, USA),
phycoerythrin (PE)-CCR2 (clone 475301, R&D Systems,
Minneapolis, MN, USA), PE-Cy™5-CD45 (clone 30-F11),
Brilliant Violet 711™-CD3ε (clone 145-2C11), allophyco-
cyanin (APC)-Ly6C (clone, AL-21) from BD Biosciences,
Brilliant Violet 421™-Ly6G (clone 1A8, BioLegend, San
Diego, CA, USA), and Alexa Fluor® 700-CD11b (clone
M1/70, eBiosciences, San Diego, CA, USA) for 30 mi-
nutes at 4 °C in the dark. Other antibodies used include:
fluorescein isothiocyanate (FITC)-CD335 (NKp46)
(clone 29A1.4) and APC-CD49b (clone DX5) from BD
Biosciences, and PE-F4/80 (clone CI:A3-1, AbD Serotec,
Kidlington, UK). For the lymphocyte flow cytometry
panel, 106 cells were incubated with PE-CD4 (clone
GK1.5), PE-Cy™5-CD45 (clone 30-F11), PE-Cy™7-CD25
(clone PC61), Brilliant Violet 711™-CD3ε (clone 145-
2C11), APC-CD19 (clone, 1D3) from BD Biosciences,
Brilliant Violet 421™-CD8a (clone 53–6.7, BioLegend),
Alexa Fluor® 700-CD11b (clone M1/70, eBiosciences,
San Diego, CA, USA) for 30 minutes at 4 °C. After
washing, cells were stained with 1 μl of Fixable Viability
Dye eFluor® 780 (eBiosciences) for 30 minutes at 4 °C in
the dark. Cell samples from the lymphocyte panel were
stained with the Foxp3/transcription factor staining
buffer set from eBiosciences. Briefly, cells were incubated
in 1 ml of the fixation/permeabilization working solution
for 30 minutes at 4 °C; cells were washed and left in 1×
permeabilization buffer overnight at 4 °C in the dark. Cells
were resuspended in 100 μl of 1× permeabilization buffer
and stained with Alexa Fluor® 488-Foxp3 (clone FJK-16 s,
eBiosciences) for 30 minutes at room temperature in the
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dark. After the final wash, all cells were resuspended in
500 μl of wash buffer for analysis.
Samples were run on the LSRII and LSR Fortessa (BD
Biosciences) benchtop flow cytometers at the University
of Wisconsin Carbone Cancer Center (UWCCC) Flow
Cytometry Facility. Each experiment was standardized
using Sphero™Rainbow Fluorescent Particles (Mid-Range)
(Spherotech Inc., Lake Forest, IL, USA). LSRII and LSR
Fortessa sensitivities were optimized during the initial run
of the experiment. Rainbow beads were collected at those
optimized settings and median fluorescent intensity (MFI)
target values were recorded in each channel. For every
run, rainbow beads were acquired first. LSRII and LSR
Fortessa voltages were adjusted until the bead peaks hit
the MFI target value (±10 %). The instrument was com-
pensated using UltraComp eBeads (eBiosciences). For
each tumor sample, 25,000 live, single cell events were
collected, and for each spleen sample, 50,000 live, single
cell events were collected. Data were analyzed using
FlowJo Single Cell Analysis Software (TreeStar, Ashland,
OR, USA), and gating was established using fluorescent
minus one (FMO) controls.
Immunohistochemical analysis
Tissues (mammary tumor, mammary gland, spleen, and
lungs) were fixed in 10 % buffered formalin (Thermo
Fisher Scientific) for 48 hours. These were then placed
in 70 % ethanol and taken to the UWCCC Experimental
Pathology Laboratory (EPL) for processing. Tissues were
embedded in paraffin and sectioned, and one section
was stained with hematoxylin and eosin (H&E) at the
EPL. COL and WT tumor sections were deparaffinized
by heating at 60 °C for 25 minutes. They were then
placed in xylenes and rehydrated in gradual dilutions of
ethanol. Antigen retrieval was done in citrate buffer pH
6.0 in a boiling water bath for 15 minutes. Endogenous
horseradish peroxidase (HRP) activity was blocked by in-
cubating sections in 0.3 % H2O2 in Tris-buffered saline
(TBS) for 20 minutes at room temperature. Sections were
blocked with 5 % normal serum and 1 % BSA in TBS
(blocking solution) for 1 hour, and with Avidin/Biotin
Block (ABC, Vector Laboratories, Burlingame, CA, USA)
for 15 minutes each. Sections were incubated with primary
rat-anti-mouse Ly6G (1:1000, clone 1A8, Biolegend) for 2
hours, and with affinity purified, mouse absorbed, biotinyl-
ated anti-rat secondary IgG (Vector Laboratories) for 45
minutes. All incubations were done at room temperature.
Sections were incubated with Vectastain Universal Ready-
to-Use ABC reagent (Vector Laboratories) for 30 minutes,
stained with 3,3’ diaminobenzidine (DAB) and counter-
stained with hematoxylin (Leica, Nussloch, Germany). Sec-
tions were dehydrated in gradual dilutions of ethanol and
xylenes before mounting in Richard Allen Scientific
mounting medium (Thermo Fisher).
Slides were imaged at the University of Wisconsin –
Madison Translational Research Initiatives in Pathology
Laboratory using the Nuance™ multispectral imaging sys-
tem (PerkinElmer, Waltham, MA, USA). Eight fields per
tumor slide were captured with the 40x objective using
the Nuance™ analysis software. Ly6G-positive cells were
counted manually for each image and averaged per tumor.
Neutrophil depletion
Mice in the treated group received intra-peritoneal injec-
tions of 5.5 μg/g of InVivoMab anti mouse Ly6G (clone
1A8, BioXCell, West Lebanon, NH, USA) and mice in
the control group received 5.5 μg/g of InVivoMab rat
IgG2a (clone 2A3, BioXCell) to deplete neutrophils in
the COL and WT tumor mice. Injections were adminis-
tered every 3 days for 24 days. Mice were 9 weeks of age
at the beginning and 12 weeks of age at the conclusion
of the experiment. Systemic neutrophil depletion was
evaluated periodically by collecting blood samples
from the saphenous vein. Samples were analyzed in a
Hemavet 950FS (Drew Scientific, Waterbury, CT, USA)
whole blood counter.
Hybrid positron emission tomography (PET) and com-
puted tomography (CT) mouse imaging before and at
the end of treatment was conducted at the UWCCC
Small Animal Imaging Facility. All mice were fasted for
12 hours prior to intravenous injection of approximately
8 MBq of 2′-deoxy-2′-[18F]fluoro-D-glucose (18FDG)
(IBA-Molecular, Sterling, VA, USA) 1 hour before im-
aging. Mice were anesthetized with inhalation gas (2 %
isoflurane gas mixed with 1 L/min of pure oxygen) and
kept under a heat lamp during injection until imaging.
Mice were imaged on the Siemens Inveon Hybrid
micro-PET/CT (Siemens Medical Solutions, Knoxville,
TN, USA) in the prone position. A 10-minute PET scan
was acquired and data were histogrammed into one static
frame and subsequently reconstructed using ordered-
subset expectation maximization (OSEM) of three dimen-
sions followed by the maximum a posteriori algorithm
(matrix size = (128,128,159), pixel size = (0.776, 0.776,
0.796) mm, iterations = 18, subsets = 16, and beta smooth-
ing factor = 0.004). Data were not corrected for attenuation
or scatter.
Data were analyzed using the Siemens Inveon™ Research
Workplace (Siemens Medical Solutions). Source CT 3D
images were co-registered with target PET 3D images.
Date, time, and dose (Mbq) were entered for each data
point (mouse). PET and CT scales were set at specific
minimum and maximum percent injection dose per gram
(%ID/g) and applied to every data point. Regions of inter-
est (ROIs) were drawn at any mammary gland that had an
FDG uptake threshold value between 7.5 and 27%ID/g
based on background region of interest (ROI) reading
(muscle) and image contrast. ROI data collected included
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volume (mm3), mean %ID/g, minimum %ID/g, and max-
imum %ID/g. Maximum intensity projections (MIPs) were
collected for each hybrid micro-PET/CT mouse 3D image
with and without ROIs. The number of ROIs per mouse
was counted to generate the number of tumors per
mouse; adding the volume of all tumors in each mouse
generated tumor burden.
Blood, tumors, spleens, and lungs were collected at the
end of the experiment. Tissues were fixed as mentioned
before. Neutrophil depletion and changes in tumor and
spleen immune cell populations were determined by flow
cytometry as explained before. Cell markers used included
PE-Cy™5-CD45 (clone 30-F11), Brilliant Violet 711™CD3ε
(clone 145-2C11), APC-CD49b (clone DX5), and FITC-
CD335 (NKp46) (clone 29A1.4) from BD Biosciences,
Brilliant Violet 421™-Ly6G (clone 1A8, BioLegend), Alexa
Fluor® 700-CD11b (clone M1/70, eBiosciences), and
PE-F4/80 (clone CI:A3-1, AbD Serotec).
Lungs were paraffin-embedded and sectioned at the
UWCCC EPL. Neutrophil counts in tumors and lungs
were taken to validate flow cytometry data. Immunohis-
tochemical analysis was conducted using anti-Ly6G as
previously explained. Slides were imaged at the Univer-
sity of Wisconsin – Madison Laboratory of Computa-
tional Instrumentation (LOCI) using the Olympus BX53
histology scope (Olympus, Center Valley, PA, USA).
Eight fields per tumor slide were captured with the 40x
N.A.: 0.75, UPlanFLN, W.D.: 0.51 objective (Olympus),
using Olympus cellSens Standard 1.13 software. Ly6G-
positive cells were counted manually for each image and
averaged per tumor.
Lungs were also sectioned through every 100 μm and
stained with H&E at the UWCCC EPL. Lung metastatic
lesions were imaged at 10x N.A.:0.30, UPlanFLN,
W.D.:2.1 objective at the University of Wisconsin –
Madison LOCI. The area of each lesion in each slide was
quantified using the FIJI (ImageJ) (National Institutes of
Health, Bethesda, MD, USA) software [30]. The total
number of lesions per mouse was counted, and the lar-
gest area for each metastatic lesion was collected.
Statistical analysis
All statistical analysis was conducted using GraphPad Prism
5 (GraphPad Software, La Jolla, CA, USA). The unpaired
Student t test was used for all experiments to test the
differences between means from WT and COL samples.
Differences were considered significant when p was <0.05.
Data are presented as single data points and the mean.
Results
COL and WT tumor microenvironments have inherently
distinct cytokine expression levels
We previously reported that the number of PyVT mam-
mary tumors and lung metastases in a COL background
is higher than the number of PyVT tumors and lung
metastases in a WT background [12]. To characterize
whether there is a change in the tumor-promoting COL
immune microenvironment, we conducted chemilumin-
escent ELISA to analyze the expression levels of 23 cyto-
kines found in lysed whole mammary tumors from 15-
week-old mice (Fig. 1a, b). Expression of interleukin-4
(IL-4), regulation on activation, normal T cell expressed
and secreted (RANTES, CCL5), macrophage inflamma-
tory protein 1α (MIP-1α, CCL3), and Interferon-γ (IFN-
γ) was at least two-fold higher in WT tumors compared
to COL tumors. IL-4, RANTES, and IFN-γ, are largely
involved in T cell signaling, recruitment and activation.
In contrast, in COL tumors the expression of platelet-
derived growth factor subunit B (PDGF-BB), granulocyte
monocyte-colony stimulated factor (GM-CSF), and IL-1α
was increased two-fold or more compared to WT tumors
(Fig. 2b). Of these, GM-CSF is a chemoattractant for
monocytes and neutrophils, and it enhances production
and survival of monocytes and granulocytes. These data
suggest that tumors arising in collagen-dense microen-
vironments secrete distinct cytokines and may recruit
distinct subsets of immune cells compared to tumors in
WT mice.
T lymphocyte recruitment is not altered in the COL tumor
microenvironment
The cytokine panel suggested that signaling to T cells is
greater in WT tumors compared to COL tumors. Differ-
ences in lymphocyte recruitment into WT and COL tu-
mors at 15 weeks were determined by flow cytometry
with a panel of T cell markers. The percentage of CD45
+ leukocytes found in COL tumors did not vary from
the percentage found in WT tumors (Fig. 2a, b). Thus,
we do not think that COL tumors were harder to dis-
sociate, as we were able to recover a very similar number
of immune cells to that recovered from WT tumors.
Moreover, we found no significant difference in the per-
centage of CD45+CD3+CD11b– T cells found in WT
and COL tumors (Fig. 2c, d). We also compared CD8
cytotoxic T cell and CD4 helper T cell markers in WT
and COL tumors (Fig. 2e), and found that the percent-
age of CD45+CD3+CD8+ cytotoxic T cells (Fig. 2f ) and
CD45+CD3+CD4+ helper T-cells (Fig. 3g) did not sig-
nificantly differ between WT and COL tumors. Recruit-
ment of other lymphocytes such as CD19+ B-cells and
NKp46+ natural killer (NK) cells also did not differ in
WT versus COL tumors (Additional file 1A and B).
We also quantified CD4+CD25+Foxp3+ regulatory T
cells. These cells are characterized by reducing T cell
proliferation and cytotoxicity and by contributing to
regulatory T cell expansion [31]. When comparing CD25
and Foxp3 regulatory T cell markers (Fig. 2h), the per-
centage of CD45+CD3+CD4+CD25+Foxp3+ regulatory
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T cells found in WT and COL tumors was not different
(Fig. 2i).
The overall myeloid cell populations are not altered in a
COL tumor microenvironment
The cytokine panel suggested that signaling to mono-
cytes and neutrophils is greater in COL tumors com-
pared to WT tumors. We conducted flow cytometry
analysis of cells dissociated and isolated from WT and
COL tumors at 15 weeks of age. The percentage of
CD45+ leukocytes found in COL tumors did not differ
from the percentage found in WT tumors (Fig. 3a, b).
When comparing cells expressing Ly6G versus F4/80 in
tumors, the percentage of F4/80+ macrophages from the
CD45+Ly6G– population did not significantly vary be-
tween WT and COL tumors (Fig. 3c, d). Of cells ex-
pressing CD45+CD3-CD11b+, we found no significant
difference in the percentage of Ly6G+Ly6C+ neutrophils
in COL tumors compared to WT (Fig. 3e, f ). We vali-
dated our flow cytometry results by staining formalin-
fixed paraffin-embedded tumor sections from WT and
COL tumor mice with anti-Ly6G (1A8) using DAB as
the chromogen and hematoxylin as the counterstain
(Fig. 3g). Figure 3h shows that the average number of
Ly6G+ neutrophils found in eight fields of view was not
significantly increased in COL tumors.
Some studies denote CD11b+Ly6G+Ly6C+ myeloid
cells as granulocytic myeloid-derived suppressor cells
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Fig. 1 Cytokines in tumor mice expressing the polyoma virus antigen and heterozygote for the collagen-1α chain mutation (COL) and wild-type
(WT) tumor microenvironments are inherently distinct. a Cytokine levels from whole WT and COL mammary tumor lysates determined by
chemiluminescent Mouse Cytokine ELISA Plate Array. Results are expressed as fold change: WT readings are normalized to COL readings (gray) to show
cytokines upregulated in WT tumors, and COL readings are normalized to WT readings (red) to show cytokines upregulated in COL tumors. Blue line
denotes a two-fold increase (n = 4 independent tumors). b Table indicates cytokines with a two-fold increase or greater. NGF nerve growth factor, PDGF
platelet-derived growth factor, Rantes regulation on activation, normal T-cell expressed and secreted, SCF stem cell factor, MIP macrophage
inflammatory protein, MCP monocyte chemoattractant protein, GM-CSF granulocyte monocyte-colony stimulated factor, EGF epidermal growth factor,
IFN interferon, FGF fibroblast growth factor, VEGF vascular endothelial growth factor, IGF insulin-like growth factor

























































































































































Fig. 2 (See legend on next page.)
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(MDSCs). As there was no change in the number of T
cells, specifically regulatory T cells, in WT versus COL
tumors, the Ly6G+ cells observed in the mammary tu-
mors were likely not MDSCs. Therefore, we refer to our
population of interest as Ly6G+Ly6C+ neutrophils in
the context of this study.
Spleens from COL tumor mice are enlarged, suggesting
an advanced disease state
Splenocytes were isolated to provide controls for flow
cytometry experiments. While harvesting the tissue, we
observed enlarged spleens in COL tumor mice at 15
weeks of age (Fig. 4a). Spleen weight was measured and
normalized to the total weight of each mouse. We found
a significant increase in the weight of spleens from COL
tumor mice compared to WT tumor mice (Fig. 4b).
Characterization of the immune cell profiles in the
spleens demonstrated no significant changes in CD45+
immune cells in COL spleens compared to WT spleens
(Fig. 4c), whether considering live cells or fixed cells
(Fig. 4f ). Of the cells expressing CD45+CD11b+, the
percent of Ly6G+Ly6C+ neutrophils was not signifi-
cantly increased in COL spleens compared to WT
spleens (Fig. 4d). The percent of F4/80+ macrophages
did not differ between COL and WT spleens (Fig. 4e).
Using the same lymphocyte flow cytometry cell marker
panel as above, we found that the percentage of CD45
+CD3+ T cells and T cell subsets: CD8+ cytotoxic T
cells, CD4+ helper T cells, and CD4+CD25+Foxp3+
regulatory T cells did not differ in COL spleens com-
pared to WT spleens (Fig. 4h–j). CD19+ B cells and
NKp46+ NK cells also did not differ in spleens from WT
versus COL tumor mice (Additional file 1C and D).
Complete blood counts (Additional file 2A–E), showed a
trend towards increased neutrophil to lymphocyte ratio
(p = 0.06) in COL tumor mice, which is also associated
with poor clinical outcome in a population of patients
with breast cancer [32]. These results suggest that en-
larged spleens and changes in circulating leukocyte counts
are whole-body global effects seen in tumor mice with in-
creased collagen.
We did not observe any differences in immune popu-
lations due to the Col1α1 transgene in the absence of
PyVT tumors in the mammary glands (do not express
the PyVT antigen) (Additional file 3A–E). The spleens
of normal, non-tumor-bearing COL mice were not
enlarged (Additional file 4A), their immune cell popula-
tion recruitment did not differ significantly (Additional
file 4B–F), and there were no significant changes in circu-
lating blood leukocyte counts (Additional file 5A–E).
Depleting neutrophils with anti-Ly6G reduces tumor bur-
den of COL mice
The cytokine array results suggest there may be differ-
ences in activation of neutrophils in COL mice, even if
the number of neutrophils recruited is not significantly
different. The function of Ly6G+ neutrophils in tumor
progression was studied by blocking the recruitment of
neutrophils in COL and WT tumor mice. Mice were
treated with anti-Ly6G or anti-IgG for 24 days starting at
9 weeks of age (Fig. 5a). In order to dynamically monitor
tumor growth in this transgenic (i.e., not luciferase-
labeled) model, we made use of hybrid micro PET-CT 3D
imaging using the uptake of 18FDG in WT and COL, con-
trol, and Ly6G-depleted mice. Figure 5b shows a represen-
tative maximum intensity projection from each group,
where ROIs are drawn to indicate where the tumor is and
its relative size. As expected, on the day before treatment
started (day −1), the number of tumors was the same in
both control and treatment groups (Fig. 5c, e). After 21
days, the tumor size increased due to disease progression
in the PyVT model in both the WT and COL control
arms. Antibody-depletion of Ly6G+ neutrophils signifi-
cantly slowed the progression of cancer by reducing the
number of COL tumors, but not the number of WT tu-
mors after 21 days (Fig. 5c, e). The total tumor burden in
WT tumor mice increased over time and was not attenu-
ated by treatment with anti-Ly6G (Fig. 5d). In contrast,
the tumor burden decreased with anti-Ly6G treatment in
COL mice after 21 days (Fig. 5f). Figure 5g–j displays the
mean and maximum percent injection dose per gram of
each tumor, and demonstrates that 18FDG uptake in-
creases with progression of the disease, but does not
change with neutrophil depletion in WT nor COL tumors.
PET imaging is a non-invasive imaging modality that uti-
lizes tumor-linked increase in glucose uptake and metab-
olism to image mammary tumors [33, 34]. Our results
show that glucose uptake does not change with treatment
or the collagen density of tumors, and therefore we con-
clude that the changes seen in the number of tumors and
tumor volume is a direct effect of blocking Ly6G+
neutrophils.
(See figure on previous page.)
Fig. 2 Lymphocyte recruitment is not altered in late-stage collagen-dense tumors. a Flow cytometry gates used to determine lymphocytes.
b Percentage of CD45+ immune cells in wild-type (WT) and collagen-dense (COL) mammary tumors (n = 6). c Flow cytometry of CD45+
cells comparing CD3 to CD11b in WT (left) and COL (right) mammary tumors, and the percentage of CD45+CD3+ T-cells present (n = 7)
(d), CD45+CD3+CD8+ cytotoxic T-cells (e and f), CD45+CD3+CD4+ helper T-cells (e and g), and CD45+CD3+CD4+CD25+Foxp3+ regula-
tory T cells (h and i) (n = 6). Purple number (lower right) represents the number of total events in each graph. These cells were fixed for
intracellular staining. FSC forward scatter, SSC side scatter, PE phycoerythrin








































































































































Fig. 3 (See legend on next page.)
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Tumors isolated from control and treated groups were
analyzed by flow cytometry to understand the effect of
depleting neutrophils on immune cell recruitment.
Figure 6a and g shows that the percentage of CD45+ im-
mune cells was similar in all groups of both tumors and
spleens. To evaluate depletion of neutrophils, we quanti-
fied the percentage of Ly6G+ neutrophils from immune
cells that were CD45+CD3-CD11b+ (Fig. 6b, h). At 12
weeks, anti-Ly6G treatment decreased neutrophil num-
bers in both WT and COL tumors. Neutrophil depletion
was confirmed in spleens of WT and COL tumor mice,
demonstrating a significant depletion in Ly6G+ neutro-
phils with antibody treatment (Fig. 6h). Interestingly,
treatment with anti-Ly6G significantly increased the
percentage of F4/80+ macrophages in WT tumors, but
not in COL tumors, which had variable numbers of F4/
80+ macrophages in both control and treatment arms
(Fig. 6c). Data from spleens also showed the trend of
increased F4/80+ macrophages in treated WT spleens.
(Fig. 6i). Changes in the number of NK cells were not
observed in tumors and spleens (Additional file 6A and
C). No spleen enlargement occurred upon anti-Ly6G
treatment at 12 weeks (Additional file 6B). Nor were
there other global effects due to anti-Ly6G treatment,
such as changes in the number of circulating blood
cells (Additional file 7A–E).
Depleting neutrophils with anti-Ly6G reduces the number
of lung metastases in COL but not WT mice
Lungs from WT and COL mice from both control and
Ly6G-depleted arms were sectioned and the number of
metastatic lesions throughout the whole lung deter-
mined. Anti-Ly6G-treated COL mice had an 80 % re-
sponse to treatment; only one out of six mice had lung
metastases. In contrast, all Ly6G-depleted WT mice de-
veloped metastatic lesions (Fig. 7a). In fact, treatment
with anti-Ly6G increased the number of WT animals
with metastases and the total number of metastases
(Fig. 7b–f ). The number of Ly6G+ neutrophils in the
lungs was quantified by immunohistochemical analysis
(Additional file 8A and B). There was no correlation
between the numbers of Ly6G+ neutrophils found in
the lungs and the number of lung metastatic lesions
(Additional file 8C).
Discussion
Although mammographic density is associated with in-
creased risk of developing breast cancer, the mechanisms
underlying this increased risk are poorly understood.
High mammographic density is associated with changes
in the stroma, including an increase in collagen 1 [8–10].
Here we use the COL MMTV-PyVT model, which has in-
creased collagen deposition, a higher tumor incidence,
and more metastases compared to tumors in WT animals
[12]. Now, we seek to further characterize the mechanisms
by which increased stromal collagen enhances tumor pro-
gression by identifying immune cell populations present
in the COL tumor microenvironment and their effect on
tumor progression. The pro-tumor progression role of
leukocyte infiltrates has been shown in the MMTV-PyVT
mammary tumor model, but not in COL mammary tu-
mors [35–37]. The expression of cytokines GM-CSF, IL-
1α, and PDGF-BB, is upregulated in tumors from COL
mice, while IL-4, MIP-1a, RANTES, and IFN-γ expression
is increased in tumors from WT mice. These differences
suggest there is an altered host response for tumors aris-
ing in collagen-dense microenvironments.
Despite differences in cytokine profiles, we did not see
a significant change in the recruitment of distinct im-
mune cell populations comparing WT to COL tumors.
Rather, there was a functional difference in the role of
neutrophils, as depletion of Ly6G+ neutrophils with
anti-Ly6G (1A8) antibody diminishes tumor progression
specifically in COL mice but has little effect on WT
Ly6G-depleted tumors. Most importantly, depletion of
neutrophils with anti-Ly6G significantly inhibited lung
metastasis in COL mice, but did not diminish metastases
in WT mice. Thus, we found that neutrophils have a
tumor promoting effect specifically in the context of COL
mammary tumors, but do not significantly contribute to
progression and metastasis in WT tumors.
Others have also performed similar neutrophil deplet-
ing studies using anti-Ly6G (1A8) in orthotopic models
[23, 28, 38, 39], but these studies did not investigate the
role of collagen density. These studies present conflict-
ing evidence on whether neutrophils play a role in breast
cancer metastasis. While treating orthotopic 66c14
mouse mammary tumors with anti-Ly6G decreases lung
metastasis [28], depletion of neutrophils in orthotopic
(See figure on previous page.)
Fig. 3 Late-stage collagen-dense mammary tumor recruitment of myeloid cells is not altered. a Flow cytometry gates used to determine myeloid
cells. b Percentage of CD45+ immune cells in wild-type (WT) and collagen-dense (COL) mammary tumors at 15 weeks (n = 6, each of which was
an independent pair of age-matched littermate WT and COL mice). c Flow cytometry of CD45+CD3– cells comparing Ly6G to F4/80 in WT (left)
and COL (right) mammary tumors. Purple number represents the number of total events in each graph. d Percentage of CD45+CD3-CD11b+ cells
that are F4/80+ macrophages in WT and COL mice. e Flow cytometry of CD45+CD11b+CD3– cells comparing Ly6C to Ly6G in WT (left) and COL
(right) mammary tumors; f the percentage of CD45+CD3-CD11b+ Ly6G+Ly6C+ neutrophils present. g Immunohistochemical analysis of WT (left)
and COL (right) mammary tumors. Tumors were stained with Ly6G (1A8) in diaminobenzidine and counterstained with hematoxylin. Scare bar 50
um. h average number of Ly6G+ cells found in eight fields of view per tumor slide (n = 4)
























































































































































































































Fig. 4 (See legend on next page.)
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MMTV-PyVT or 4T1 mouse mammary carcinoma
models does not affect primary tumor size and results in
increased lung metastasis [27]. Tabariés et al. recently
demonstrated that Ly6G+ granulocytes are recruited to
lung and liver metastases in the 4T1 model. In their
study, depleting neutrophils with anti-Ly6G did not
affect lung metastasis, but it did reduce liver metastasis
[23]. All of these models rely on cell lines or surgical
procedures for the creation of tumors and metastases.
An intriguing possibility is that the conflicting results
may be due to different wound-healing and fibrotic re-
sponses in these different studies, although changes in
the ECM were not determined. Here, we used the
MMTV-PyVT model, which develops spontaneous me-
tastasis starting after 10 weeks of age [40] and does not
require surgical intervention that may confound the re-
sults with variable wound-healing effects. In the current
study, anti-Ly6G treatment had no effect on lung metas-
tases in WT mice, but significantly decreased metastases
in COL mice.
Our flow cytometry analysis of immune cell types
showed an increase in the number of CD11b+F4/80+
macrophages in treated WT tumors. Because TAMs
have an established role in tumor progression and me-
tastasis [19, 41], the increase in macrophages may carry
on with invasion and metastasis in the MMTV-PyVT tu-
mors even after depletion of Ly6G+ cells in WT mice. A
role for macrophages in metastasis following Ly6G
depletion is supported by our observation that the
only individual mouse with metastasis in the treated
COL group also had the largest recruitment of
CD11b+F4/80+ macrophages (data not shown). In the
COL mouse model collagen I is increased throughout the
whole animal. We hypothesized that COL lungs can also
recruit Ly6G+ neutrophils, but our results did not support
this hypothesis, because the number of lung meta-
static lesions did not correlate with the number of
Ly6G+ neutrophils found near the lung metastases.
It is not entirely clear why depleting Ly6G+ neutro-
phils slows tumor growth in COL mice but not WT
mice. This finding demonstrates that Ly6G+ neutrophils
have an important role in COL tumor progression, but
not in WT tumor progression. Possibly the Ly6G+ neu-
trophils in the COL tumors are polarized towards a pro-
tumor phenotype compared to the Ly6G+ neutrophils in
WT tumors. If Ly6G+ neutrophils in WT tumors are
not pro-tumorigenic, depleting them would have little
effect, which is what we observed. The idea that there is
a fundamental difference in the host response in the
COL versus the WT tumor microenvironment is consistent
with our finding that there are differences in the cytokines
released within COL compared to WT tumors.
Studies of mesothelioma and lung carcinoma lines
injected into the flank of mice have been used to dem-
onstrate the polarization of neutrophils, identifying a
tumor-associated neutrophil (TAN) population analo-
gous to TAMs. TANs can have anti-tumorigenic (N1) or
pro-tumorigenic (N2) phenotypes, where the predomin-
ant N2 phenotype is driven by the presence of trans-
forming growth factor (TGF)-β [38]. These models also
show that TANs at early stages of tumor growth are
more cytotoxic to tumor cells by either directly killing
tumor cells or by secreting reactive oxygen species
(ROS), whereas later in tumor development, they acquire
a more tumor-supportive phenotype [39]. In pancreatic
cancer, neutrophils residing within the tumors express
MMP-9, which then liberates vascular endothelial growth
factor (VEGF) and promotes angiogenesis [42]. Ly6G+
neutrophils are recruited preferentially to liver metastases
in the 4T1 model, where they are alternatively polarized
towards an N2, pro-tumorigenic phenotype [23]. Several
studies reveal that N2 neutrophils express MMP9, NE,
and CXCR4, among other pro-tumor mediators [43–45].
We have found no evidence that the collagen-dense
tumor microenvironment facilitates the expression of
these markers in Ly6G+ neutrophils when compared
to neutrophils in non-dense tumors (data not shown).
Our results are consistent with a more general notion that
the cell-ECM interactions occurring in the collagen-dense
microenvironment are associated with a neutrophil-
dependent tumor progression and metastatic process.
In vitro studies of neutrophil biology have demonstrated
the ability of neutrophils to migrate in 3D collagen I
matrices [46]. Neutrophils can also adhere and become
activated in type I collagen [47]. Peptides derived from
collagen breakdown are chemotactic for neutrophils in
vivo and in vitro [48]. These neutrophil capabilities, espe-
cially neutrophil migration in response to chemoattrac-
tants, involve integrin-β2, integrin-α2, and integrin-β1.
The two latter integrins mediate cell adhesion to collagen
(See figure on previous page.)
Fig. 4 Spleens from late-stage collagen-dense tumor mice are enlarged relative to wild-type (WT) mice. a Example spleens from WT (left) and
tumor mice expressing the polyoma virus antigen and heterozygote for the col1a1 mutation (COL) (right). Note the increased size of the COL
spleens. b Spleen weight (mg) normalized to mouse weight (g) from both WT and COL mice (n = 7). c Percentage of CD45+ immune cells, d
Ly6G+Ly6C+ neutrophils and e F4/80+ macrophages found in WT and COL spleens, determined by flow cytometry as in Fig. 3. Note that there is
a trend toward decreased CD45+ immune cells (p = 0.13) and increased Ly6G+Ly6C+ neutrophils in COL tumors (p = 0.18) (f) CD45+
immune cells (lymphoid panel, fixed cells), (g) CD3+ T-cells, (h) CD8+ cytotoxic T-cells, (i) CD4+ T helper cells, and (j) Foxp3+ T regulatory cells
found in WT and COL spleens, determined by flow cytometry as in Fig. 2)
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Fig. 5 Neutrophil depletion with anti-Ly6G antibody reduces collagen-dense tumor formation as measured by 18FDG-PET glucose uptake.
a Experimental time line showing timing of injections of 5.5 μg/g of control IgG (2A3) or Ly6G (1A8) into the peritoneal cavity of wild-type (WT)
tumor mice and tumor mice expressing the polyoma virus antigen and heterozygote for the col1a1 mutation (COL) mice (n = 5–6 in each group) at 9
weeks of age for 24 days. Yellow arrows indicate day of 2’-deoxy-2’-[18F]fluoro-D-glucose (18FDG) hybrid positron emission tomography
(PET)-computed tomography (CT) imaging. Black arrows indicate day of treatment. Red arrows indicate day of blood collection. Green arrow indicates
day of tissue collection (tumors, spleens, and lungs). b Detection of mammary tumors by 18FDG-PET/CT. Coronal sections of co-registered 18FDG-PET
and CT images of WT and COL tumor mice before treatment at 9 weeks of age (Day −1) and after treatment at 12 weeks of age (Day 21). Regions of
interest are drawn and colored at the mouse mammary glands with visible tumors. Physiologic tracer uptake in heart (H), kidneys (K), and
bladder (B) is marked. Total number of tumors in c WT mice and e COL mice as determined by 18FDG-PET at day −1 (D –1) and day 21
(D 21). Sum of the mass (mm3) of all tumors per WT (d) and COL mouse (f) at day −1 and day 21 (n = 5–6; each data point equals one
mouse). Note that there is a trend toward decreased tumor burden in anti-Ly6G-treated COL tumors (p = 0.24). g Mean glucose uptake
(percent injection dose per gram (%ID/g) in WT and COL (i) tumors at day −1 and day 21. h Maximum glucose uptake (%ID/g)) in WT
and j COL tumors at day −1 and day 21 (n = 32–46; each data point equals one tumor)
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Fig. 6 Immune cell recruitment to tumors and spleens treated with anti-Ly6G. Percentage of CD45+ immune cells (a), Ly6G+ neutrophils
(b), F4/80+ macrophages (c), and CD3+ T cells (d) in wild-type (WT) and collagen-dense (COL) mammary tumors from 12-week-old mice
treated with control IgG or Ly6G (n = 5–6) obtained by flow cytometry at day 24 of the treatment regimen (described in Fig. 5a). Immunohistochemistry
of tumors from the four treatment groups (e). Tumors were stained with Ly6G (1A8) in DAB and counterstained with hematoxylin. Scare bar = 100 um.
Average number of Ly6G+ cells found in eight fields of view per tumor slide (n = 3) (f). Percentage of CD45+ immune cells (g), Ly6G+ neutrophils
(h), F4/80+ macrophages (i), and CD3+ T-cells (j) in spleens of the same treated and untreated WT and COL mice, as shown in a–d
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I fibrils [49, 50]. Although rapid leukocyte migration
in response to chemokines can be integrin-independent
[51], neutrophil chemotaxis in collagen I is also mediated
by the collagen receptor, discoidin domain receptor 2
(DDR2). DDR2 regulates neutrophil directionality and
persistence by releasing MMPs (MMP-8) that cleave
collagen [52]. These studies support the recruitment
of neutrophils to COL microenvironments in vivo.
Our data suggest that tumors arising in a collagen-
dense microenvironment are fundamentally different
from those arising in a non-dense microenvironment, as
there are key differences in cytokine signals that support
tumor progression. All cytokines have specific roles in
wound healing or infection, but once the immune sys-
tem is challenged with cancer, some of these functions
are co-opted by the tumor. The presence and function
of Ly6G+Ly6C+ neutrophils in COL mammary tumors
is likely supported by increased GM-CSF levels com-
pared to WT tumors. This proinflammatory cytokine
stimulates proliferation and induces maturation of gran-
ulocyte and monocyte progenitor cells. GM-CSF has
been described as a strong chemoattractant for mouse
and human neutrophils [53, 54] that can differentiate
monocytes into dendritic cells and polarize T cells into a
T helper-1 (Th-1) phenotype [55, 56]. GM-CSF can
block the angiogenic functions of tumor-associated mac-
rophages in FVB mice orthotopically injected with PyVT
tumors [57]. Moreover, GM-CSF is associated with ag-
gressive breast cancer subtypes. GM-CSF secreted by
cells derived from the FVB202 mouse model of breast
cancer with inactivated neu (Erbb2) can recruit and aid
in survival and differentiation of CD11b+GR-1+ cells,
which include CD11b+Ly6G+ cells [58]. GM-CSF se-
creted by human breast cancer cells primes plasmacytoid
b c d e
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Fig. 7 Neutrophil depletion with anti-Ly6G antibody reduces the number of dense-collagen metastatic lesions. (a) Numbers of mice with metastasis
per group. Note that all treated wild-type (WT) tumor mice developed metastatic lesions versus one tumor mouse expressing the polyoma
virus antigen and heterozygote for the col1a1 mutation (COL) (p < 0.05). Representative images of lungs with corresponding metastasis in the WT
control group (b), WT anti-Ly6G treated group (c), COL control group (d), and COL anti-Ly6G-treated group (e). Scale bar 2 mm (whole lung image) and
250 μm (metastatic lesion image). f Quantification of the number of metastatic lesions found in each mouse (n = 5–6 per group)
García-Mendoza et al. Breast Cancer Research  (2016) 18:49 Page 15 of 19
pre-dendritic cells (pDC) to polarize the immune micro-
environment toward a regulatory Th-2 phenotype [59].
Homodimer PDGF-BB is also upregulated in COL tu-
mors. High levels of PDGF-B lead to over-activity of
tyrosine kinase PDGF receptor and tumor cell prolifera-
tion. This mitogen stimulates growth, survival, and mi-
gration of mesenchymal/stromal cells [60]. Breast cancer
cell-secreted PDGF targets stromal cells and initiates
tumor desmoplasia [61]. In vitro, PDGF-BB is a chemo-
attractant for neutrophils and monocytes, and can acti-
vate human neutrophils [62, 63]. Thus, our finding of
elevated PDGF-BB in a dense collagen microenviron-
ment is consistent with an increase in neutrophil activa-
tion. Il-1α is not commonly found in the circulation
except in severe disease. IL-1α can induce matrix deg-
radation and remodeling by breast cancer fibroblasts.
Breast cancer cells can secrete IL-6 and IL-8 in response
to IL-1α [64]. Although not part of the cytokine array,
IL-8 (KC, MIP-2, and LIX homologues in mouse) is a
major neutrophil chemoattractant [65, 66]. Our data
suggest that all of these contribute to the progression of
mammary cancer in the COL tumor microenvironment
through the interplay of different components of the
tumor microenvironment (collagen, cancer cells, fibro-
blasts, and neutrophils). It has yet to be determined
exactly which cell type contributes to the increased pro-
duction of these cytokines in this model. Tumor cell cyto-
kine secretion has been widely studied in vitro, but new
techniques must be developed to answer these questions
in a complex, in vivo COL tumor microenvironment.
Of the signals downregulated in collagen -dense mam-
mary tumors, CCL5 is the chemokine that has the greatest
differential expression in WT mammary tumors. It is pro-
duced by activated T cells and is a strong T cell chemo-
attractant. The role of CCL5 in breast cancer progression
and metastasis has been established: this includes upregu-
lation of MMP secretion, pro-tumor effects by generating
MDSC in the bone marrow, and a reduction in metastasis
when low levels of CCL5 are expressed [67–70]. Also up-
regulated in WT tumors, IL-4 is one of the most studied
Th-2 cytokines [71]. Recent studies of IL-4/IL-4 receptor
(IL-4R) signaling in breast cancer cells in vitro and in vivo
show enhanced cell survival and proliferation via signal
transducer and activator of transcription (STAT)/protein
kinase B (AKT)/mitogen-activated protein kinase (MAPK)
signaling. It is also produced by activated T cells and pro-
motes differentiation, survival, and proliferation of B and
T lymphocytes via IL4R signaling [72].
T cells (CD3+ T lymphocytes, especially CD8+ T cells)
have also been shown to respond to the potent chemo-
attractant, CCL3 [73]. CCL3 can recruit and activate
monocytes and is involved in anti-tumor activities as a Th-
1 cytokine and increasing NK cell cytotoxicity [74]. On the
other hand, CCL3 has been implicated in promoting breast
cancer metastasis to the lungs [75]. Also a Th-1 cytokine,
IFN-γ works with T lymphocytes to regulate tumor cell im-
munogenicity by preventing the development of spontan-
eous epithelial carcinoma [76]. The presence of these
cytokines only in WT tumors leads to the hypothesis that
COL tumors have reduced T cell signaling (recruitment
and activation), which may account for their increased
tumor incidence and metastasis. We found no major differ-
ences in the recruitment of T cells and subgroups in WT
versus COL mammary tumors and spleens. B cell and NK
cell populations also did not differ in recruitment. These
results open the doors to studies of lymphocyte activation,
proliferation, and cytotoxicity in either 3D in vitro collagen
gels or in the MMTV-PyVTcollagen-dense model.
Conclusions
We found that MMTV-PyVT tumors arising in a dense
collagen microenvironment have altered cytokine ex-
pression compared to tumors arising in a non-dense
microenvironment. Cytokines involved in neutrophil
maturation and recruitment, including GM-CSF, PGDF-
BB, and IL-1α, were altered in dense-collagen tumors.
Depletion of Ly6G+ neutrophils diminished tumor for-
mation, tumor burden, and lung metastasis, specifically
in collagen-dense mammary tumors. Identifying neutro-
phils as key players in COL mammary tumor progres-
sion has important clinical implications for patient
populations with mammographically dense breast tissue.
Although more research is necessary, tumor-associated
neutrophils may be useful prognostic markers and pos-
sible targets for breast cancer therapy, especially for pa-
tients with dense breast tissue.
Additional files
Additional file 1: Quantification of B cell and NK cells found in late-
stage mammary tumors. A The percentage of CD45+CD3- cells that are
CD19+ B cells in WT and COL tumors and C spleens at 15 weeks. B The
percentage of CD45+CD3- cells that are Nkp46+ NK cells in WT and COL
tumors and D spleens at 15 weeks. (PDF 293 kb)
Additional file 2: Tumor mice complete blood counts at late tumor
stages. A White blood cell, B lymphocyte, C monocyte, and D neutrophil
counts in 103 per μl of blood from WT and COL tumor mice at 15 weeks.
Blood was obtained by a retro-orbital bleeding procedure and counted
on a Hemavet 950FS hematology system. E Neutrophil to lymphocyte
ratio (NLR) a.u. Green dash line denotes no change (NLR = 1) (n = 5).
(PDF 311 kb)
Additional file 3: Quantification of immune cells in wild-type and
collagen-dense non-tumor mammary glands. A Percentage of CD45+
immune cells in WT and COL mammary glands at 15 weeks (n = 3, of
which each is an independent pair of age-matched littermate WT
and COL non-tumor mice). B Percentage of CD45+CD3-CD11b+ cells
that are F4/80+ macrophages in mammary glands. C Percentage of
CD45+CD3-CD11b+ cells that are Ly6G+Ly6C+ neutrophils. D Percentage
of CD45+CD3- cells that are Nkp46+ NK cells. E Percentage of CD45+CD3+
T-cells in mammary glands, determined by flow cytometry as in Fig. 1.
(PDF 313 kb)
García-Mendoza et al. Breast Cancer Research  (2016) 18:49 Page 16 of 19
Additional file 4: Quantification of immune cells in spleens from wild-type
and collagen-dense non-tumor mice. A Spleen weight (mg) normalized to
mouse weight (g) from both WT and COL mice (n= 3). B Percentage of
CD45+ immune cells, C CD45+CD3-CD11b+ cells that are F4/80+, D CD45
+CD3-CD11b+ cells that are Ly6G+Ly6C+ neutrophils, E CD45+CD3-CD11b+
cells that are Nkp46+ NK cells, and F CD45+CD3+ T cells found in WT and
COL spleens from non-tumor mice at 15 weeks, determined by flow
cytometry as in Additional file 3. (PDF 327 kb)
Additional file 5: Non-tumor mice complete blood counts at 15 weeks
of age. A White blood cell, B lymphocyte, C monocyte, and D neutrophil
counts in 103 per μl of blood from WT and COL non-tumor. Blood was
obtained as in Additional file 2. E Neutrophil to lymphocyte ratio (NLR)
a.u. Green dash line denotes no change (NLR = 1) (n = 3). (PDF 304 kb)
Additional file 6: Recruitment NK cells in neutrophil-depleted tissues.
A The percentage of CD45+CD3– cells that are Nkp46+ NK cells in
anti-Ly6G treated or IgG control WT and COL tumors at 12 weeks.
B Spleen weight (mg) normalized to mouse weight (g) from anti-Ly6G
treated and IgG control WT and COL tumor mice. C The percentage of
CD45+CD3– cells that are Nkp46+ NK cells in anti-Ly6G treated or IgG
control WT and COL spleens at 12 weeks. (PDF 300 kb)
Additional file 7: Complete blood counts at different time points
during neutrophil depleting study. A White blood cell, B monocyte,
C granulocyte, and D lymphocyte count in 103 per μl from treated and
control WT and COL mice obtained by saphenous vein bleeding, and
counted on a Hemavet 950FS hematology system. E Neutrophil to
lymphocyte ratio (NLR) a.u. (n =5 or 6). (PDF 336 kb)
Additional file 8: Neutrophil counts in metastatic lungs do not correlate
with number of metastases in depletion study. A Immunohistochemical
analysis of lungs from the four treatment groups. Lungs were stained
with Ly6G (1A8) in DAB and counterstained with hematoxylin. Scare bar
100 um. B Average number of Ly6G+ cells found in eight fields of view
per slide (n = 3). C Average number of Ly6G+ cells per lung versus the
number of metastatic lesions per lungs. (JPG 558 kb)
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protein-1α; MMP: matrix metalloproteinase; MMTV-PyVT: mouse mammary
tumor virus - polyoma virus middle T antigen; N1: anti-tumor neutrophil;
N2: pro-tumor neutrophil; NE: neutrophil elastase; NK cell: natural killer cell;
NRL: neutrophil to lymphocyte ratio; OSEM: ordered-subset expectation
maximization; PCR: polymerase chain reaction; pDC: plasmacytoid
predendritic cells; PDGF-BB: platelet-derived growth factor subunit B
homodimer; PE: phycoerythrin; PET: positron emission tomography;
RANTES: regulation on activation, normal T-cell expressed and secreted;
ROI: region of interest; ROS: reactive oxygen species; STAT: signal transducer
and activator of transcription; TAM: tumor-associated macrophage;
TAN: tumor-associated neutrophil; TBS: Tris-buffered saline; TGF: transforming
growth factor; TNF: tumor necrosis factor; UWCCC: University of Wisconsin
Carbone Cancer Center; VEGF: vascular endothelial growth factor; WT: tumor
mice expressing the polyoma virus antigen, but negative for the collagen-1α
chain mutation.
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